Emyria and PAX Centre have announced a collaboration to develop a scalable MDMA-assisted therapy model for patients with complex PTSD.

PAX Centre is one of Australia’s leading trauma-focused, multidisciplinary psychiatric services specialising in the treatment of complex trauma.

The collaboration is part of Emyria’s longer-term goal to establish a network of trained therapists and psychiatrists to provide MDMA-assisted therapy – via ethics approved clinical trials and the Authorised Prescriber pathway – to appropriately diagnosed patients from July 1st 2023.

Read more: Emyria partners with PAX Centre for MDMA-assisted therapy | Emyria Investor Hub